Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tocilizumab in moderate to severe rheumatoid arthritis
ACTRN12609000747224Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Incidence of adverse events and serious adverse events. Started Mar 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12609000747224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000747224.